Amylin Pharmaceuticals to Present at Deutsche Bank 37th Annual Health Care Conference

SAN DIEGO--(BUSINESS WIRE)--Apr 30, 2012 - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Deutsche Bank 37th Annual Health Care Conference on Monday, May 7, 2012 at 2:10 p.m. ET / 11:10 a.m. PT in Boston. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.

The presentation will be webcast through the “Investors” section of Amylin's corporate website at www.amylin.com, and a recording will be made available following the event. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin is committed to delivering novel therapies that transform the way diabetes and other metabolic disorders are treated. Amylin is headquartered in San Diego, Calif., and has a commercial manufacturing facility in Ohio. More information on Amylin Pharmaceuticals is available at www.amylin.com.

Contact: Amylin Pharmaceuticals, Inc.
Investors
Christine Everett-Zedelmayer
(858) 458-8517
christine.everett@amylin.com
or
Media
Alice Izzo
(858) 642-7272
alice.izzo@amylin.com

 

Posted: April 2012

View comments

Hide
(web2)